Cargando…
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone
INTRODUCTION: Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) has been shown to enhance breast cancer cell survival and confer resistance to chemotherapeutic agents. We studied the prognostic and predictive value...
Autores principales: | Xu, Binghe, Guan, Zhongzhen, Shen, Zhenzhou, Tong, Zhongshen, Jiang, Zefei, Yang, Junlan, DeSilvio, Michelle, Russo, Mark, Leigh, Meggan, Ellis, Catherine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187249/ https://www.ncbi.nlm.nih.gov/pubmed/25056500 http://dx.doi.org/10.1186/s13058-014-0405-y |
Ejemplares similares
-
Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen
por: Yardley, Denise A., et al.
Publicado: (2012) -
Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer
por: McCorkle, J. Robert, et al.
Publicado: (2021) -
Interactions of Phosphatase and Tensin Homologue (PTEN)
Proteins with Phosphatidylinositol Phosphates: Insights from Molecular
Dynamics Simulations of PTEN and Voltage Sensitive Phosphatase
por: Kalli, Antreas C., et al.
Publicado: (2014) -
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies
por: Tan, A R, et al.
Publicado: (2014) -
Synergistic Antitumor Effects on Drug-Resistant Breast Cancer of Paclitaxel/Lapatinib Composite Nanocrystals
por: Wang, Jun, et al.
Publicado: (2020)